Anurag Kedia, MD
Family Medicine · Tallmadge, OHNPI 1922073956
Payments from drug & device makers
Across 375 payments — averaging $21.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$3K
- GSK$877
- Pfizer$666
- AbbVie$565
- Novo Nordisk$334
- AstraZeneca$311
- plus $2K from 27 others
What the payments were for
- Speaking & faculty fees$2,50031%
- Food & beverage$5,48668%
- Education$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 63 | $3,073 |
| GSK | 68 | $877 |
| Pfizer | 56 | $666 |
| AbbVie(2 entities) | 36 | $565 |
| Novo Nordisk | 25 | $334 |
| AstraZeneca | 21 | $311 |
| Coloplast | 2 | $200 |
| Lilly USA, LLC | 13 | $184 |
| Astellas Pharma US Inc | 10 | $164 |
| Dendreon Pharmaceuticals LLC | 1 | $144 |
| Novartis | 10 | $143 |
| Sanofi | 1 | $133 |
| Esperion Therapeutics, Inc. | 9 | $131 |
| Boston Scientific | 1 | $125 |
| Boehringer Ingelheim | 7 | $110 |
| Amgen | 6 | $110 |
| Axsome Therapeutics, Inc. | 4 | $98 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $83 |
| Bayer | 4 | $76 |
| Phathom Pharmaceuticals, Inc. | 5 | $74 |
| Radius Health, Inc. | 4 | $66 |
| Abbott | 4 | $65 |
| Teva Pharmaceuticals USA, Inc. | 3 | $55 |
| Merck | 3 | $40 |
| Exact Sciences | 2 | $37 |
| Idorsia Pharmaceuticals US Inc | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $26 |
| Kowa Pharmaceuticals America, Inc. | 2 | $25 |
| E.r. Squibb & Sons, L.L.C. | 2 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$2,608
- PROVENGE$144
- KEVZARA$133
- GENERAL BPH$125
How this compares
$8,036 in reported general payments places this provider in the 90th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $66,084 |
| EliquisApixaban | 45 | $59,497 |
| VascepaIcosapent Ethyl | 45 | $39,665 |
| FarxigaDapagliflozin Propanediol | 27 | $32,594 |
| OzempicSemaglutide | 22 | $29,748 |
| JardianceEmpagliflozin | 24 | $29,496 |
| JanuviaSitagliptin Phosphate | 19 | $28,621 |
| XareltoRivaroxaban | 11 | $15,930 |
| JanumetSitagliptin Phos/Metformin Hcl | 17 | $15,039 |
| LivaloPitavastatin Calcium | 11 | $5,119 |
| Memantine Hcl ErMemantine Hcl | 31 | $3,382 |
| Atorvastatin Calcium | 348 | $3,262 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 57 | $2,996 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 30 | $2,976 |
| Rosuvastatin Calcium | 288 | $2,650 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $877 | $66,08446 claims |
| PfizerEliquis | $666 | $59,49745 claims |
| MerckJanuvia, Janumet | $40 | $43,65936 claims |
| AstraZenecaFarxiga | $311 | $32,59427 claims |
| Novo NordiskOzempic | $334 | $29,74822 claims |
| Boehringer IngelheimJardiance | $110 | $29,49624 claims |
| Johnson & JohnsonXarelto | $12 | $15,93011 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $25 | $5,11911 claims |
| AbbVieSynthroid | $565 | $1,00853 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Tallmadge
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.